| VXRT Stock | | | USD 0.60 0.06 11.11% |
Director
Dr. Michael J. Finney serves as Director of the company. Since October 2004, Dr. Finney has served as the Managing Director of Finney Capital, a VC firm. Since 1986, Dr. Finney has served as a founder, director andor investor in various life science companies. Currently, he sits on six private boards. From 2009 to 2011, Dr. Finney served as chief executive officer of the Company since 2018.
| Age | 65 |
| Tenure | 6 years |
| Professional Marks | Ph.D |
| Address | 170 Harbor Way, South San Francisco, CA, United States, 94080 |
| Phone | 650 550 3500 |
| Web | https://vaxart.com |
Finney received an A.B. in biochemical sciences from Harvard University and a Ph.D. in biology from the Massachusetts Institute of Technology.
Vaxart Management Efficiency
The company has return on total asset
(ROA) of
(0.3968) % which means that it has lost $0.3968 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity
(ROE) of
(0.9166) %, meaning that it created substantial loss on money invested by shareholders. Vaxart's management efficiency ratios could be used to measure how well Vaxart manages its routine affairs as well as how well it operates its assets and liabilities.
Vaxart Inc currently holds 26.51
M in liabilities with Debt to Equity
(D/E) ratio of 0.09, which may suggest the company is not taking enough advantage from borrowing. Vaxart Inc has a current ratio of 8.48, suggesting that it is
liquid enough and is able to pay its financial obligations when due. Note, when we think about Vaxart's use of debt, we should always consider it together with its cash and equity.
Similar Executives
Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company is headquartered in South San Francisco, California. Vaxart operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 110 people. Vaxart Inc (VXRT) is traded on NASDAQ Exchange in USA. It is located in 170 Harbor Way, South San Francisco, CA, United States, 94080 and employs 109 people. Vaxart is listed under Biotechnology category by Fama And French industry classification.
Management Performance
Vaxart Inc Leadership Team
Elected by the shareholders, the Vaxart's board of directors comprises two types of representatives: Vaxart inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Vaxart. The board's role is to monitor Vaxart's management team and ensure that shareholders' interests are well served. Vaxart's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Vaxart's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Rajesh Kapoor, Senior Quality | |
| Shaily Garg, Senior Management | |
| Brant Biehn, Sr Operations | |
| Cezar MBA, Pres CEO | |
| Sarah Khan, VP Resources | |
| Phillip Lee, Principal CFO | |
| Steven Lo, CEO President | |
| James MD, Chief Officer | |
| Michael Finney, Interim Director | |
| Fuad Ahmad, Interim Officer | |
| CPA MBA, Consultant | |
| Dr Stapleton, Chief Officer | |
| Sean Tucker, Chief Scientific Officer | |
| Edward Berg, Senior Counsel | |
Vaxart Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Vaxart a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Additional Tools for Vaxart Stock Analysis
When running Vaxart's price analysis, check to
measure Vaxart's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vaxart is operating at the current time. Most of Vaxart's value examination focuses on studying past and present price action to
predict the probability of Vaxart's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vaxart's price. Additionally, you may evaluate how the addition of Vaxart to your portfolios can decrease your overall portfolio volatility.